Brought to you by 
Paul Royalty buys Dyax's phage rights for $30mm
13 Sep 2018
Executive Summary
Dyax (therapeutic candidates for cancer and inflammation) has raised $30mm with the sale to Paul Capital Partners' Paul Royalty Fund of a tiered percentage of its revenues from its phage display licensing and funded research program (PDLFRP, which has already granted over 75 licenses) over the next 10 years. Dyax may also get an additional $5mm if the PDLFRP reaches certain predetermined revenue levels in the next 24 months. Dyax reserves the right to repurchase the rights at any time. The company will use the funds to continue the development of its hereditary angioedema and CABG programs and further the other drug candidates in its pipeline.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Molecular Diversity
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Royalty Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Paul Royalty buys Dyax's phage rights for $30mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice